Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Indivior PLC Ordinary Shares (INDV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: INDV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -4.77% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.17B USD | Price to earnings Ratio 469 | 1Y Target Price 15.67 |
Price to earnings Ratio 469 | 1Y Target Price 15.67 | ||
Volume (30-day avg) 1654822 | Beta 0.26 | 52 Weeks Range 7.33 - 22.53 | Updated Date 04/2/2025 |
52 Weeks Range 7.33 - 22.53 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -4.04% | Operating Margin (TTM) 18.73% |
Management Effectiveness
Return on Assets (TTM) 10.69% | Return on Equity (TTM) 12.2% |
Valuation
Trailing PE 469 | Forward PE - | Enterprise Value 1245171198 | Price to Sales(TTM) 0.98 |
Enterprise Value 1245171198 | Price to Sales(TTM) 0.98 | ||
Enterprise Value to Revenue 1.05 | Enterprise Value to EBITDA 14.82 | Shares Outstanding 124656000 | Shares Floating 92205340 |
Shares Outstanding 124656000 | Shares Floating 92205340 | ||
Percent Insiders 4.02 | Percent Institutions 88.2 |
Analyst Ratings
Rating 4.71 | Target Price 16 | Buy 2 | Strong Buy 5 |
Buy 2 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Indivior PLC Ordinary Shares
Company Overview
History and Background
Indivior PLC was formed in 2014 as a spin-off from Reckitt Benckiser. It focuses on developing treatments for opioid use disorder (OUD) and related conditions. Its history includes facing legal challenges related to its Suboxone product.
Core Business Areas
- OUD Treatment: Indivior's primary focus is on developing and commercializing treatments for opioid use disorder (OUD). This includes medication-assisted treatment (MAT) using buprenorphine and naloxone.
- Addiction Treatment Pipeline: Developing a pipeline of new therapies for addiction, including novel formulations and potentially new mechanisms of action.
Leadership and Structure
Indivior is led by a board of directors and a management team, with key executives responsible for strategy, operations, and research and development. The company operates with a functional structure, with departments dedicated to specific areas such as sales, marketing, and regulatory affairs.
Top Products and Market Share
Key Offerings
- SUBOXONE (buprenorphine and naloxone) Sublingual Film: A sublingual film containing buprenorphine and naloxone used to treat opioid dependence. While its market share has decreased due to generic competition, it was a major revenue generator. Competitors include generic versions of buprenorphine/naloxone films and tablets, as well as other MAT options like methadone and naltrexone.
- SUBLOCADE (buprenorphine) extended-release injection: A monthly injectable formulation of buprenorphine for the treatment of moderate to severe opioid use disorder. It is a key growth driver for Indivior. Competitors include Vivitrol (naltrexone) and other buprenorphine products like Suboxone and its generics.
- PERSERIS (risperidone) extended-release injection: An extended-release injectable formulation of risperidone for the treatment of schizophrenia in adults. This helps to diversify the portfolio beyond just addiction treatment. Competitors include other long-acting injectable antipsychotics.
Market Dynamics
Industry Overview
The market for addiction treatment is growing due to the opioid crisis and increasing awareness of mental health issues. The industry is characterized by increasing regulatory scrutiny and the rise of telehealth and digital health solutions.
Positioning
Indivior is positioned as a leader in medication-assisted treatment for opioid use disorder, particularly with its SUBLOCADE product. The company faces competition from generic manufacturers and other pharmaceutical companies with alternative treatments.
Total Addressable Market (TAM)
The TAM for OUD treatment is estimated to be in the billions of dollars annually, driven by the high prevalence of opioid addiction. Indivior is well-positioned to capture a significant share of this market with its portfolio of buprenorphine-based products.
Upturn SWOT Analysis
Strengths
- Strong brand recognition in OUD treatment
- SUBLOCADE's unique delivery method (monthly injection)
- Experienced management team
- Diversification through PERSERIS
Weaknesses
- Past legal issues and settlements
- Reliance on buprenorphine-based products
- Generic competition for SUBOXONE
- Relatively small market capitalization compared to competitors
Opportunities
- Expanding access to OUD treatment through telehealth
- Developing new formulations and treatments for addiction
- Partnerships with healthcare providers and payers
- International expansion
Threats
- Increased generic competition
- Changes in regulatory policies
- Negative publicity related to opioids
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- VTRS
- OTCQX:SWHC
- AMRX
Competitive Landscape
Indivior competes with generic manufacturers, as well as other pharmaceutical companies with alternative treatments for opioid use disorder and mental health conditions. Indivior's competitive advantage lies in its SUBLOCADE product, which offers a convenient monthly injection.
Major Acquisitions
Opiant Pharmaceuticals
- Year: 2023
- Acquisition Price (USD millions): 145
- Strategic Rationale: To expand its addiction treatment portfolio by acquiring Opiant's nasal naloxone product (NARCANu00ae) and pipeline of opioid overdose reversal products.
Growth Trajectory and Initiatives
Historical Growth: Indivior's growth has been driven primarily by the uptake of SUBLOCADE, offsetting declines in SUBOXONE sales due to generic competition.
Future Projections: Analysts project continued growth for Indivior, driven by SUBLOCADE and the pipeline of new products. Revenue is expected to increase in the coming years.
Recent Initiatives: Focus on expanding SUBLOCADE access, developing new formulations of buprenorphine, and exploring new therapeutic areas beyond OUD.
Summary
Indivior is a pharmaceutical company specializing in addiction treatment, particularly opioid use disorder (OUD). Sublocade has fueled growth as Suboxone revenues decline due to generics. However, Indivior is still small in comparison with their competitiors. It must defend its market against generic competition while growing new products like Perseris, and Opiant Narcan products and potentially expand in international markets
Similar Companies
AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
TEVA
Teva Pharma Industries Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
VTRS
Viatris Inc
VTRS
Viatris Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry News Sources
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Indivior PLC Ordinary Shares
Exchange NASDAQ | Headquaters North Chesterfield, VA, United States | ||
IPO Launch date 2014-12-29 | CEO & Executive Director Mr. Mark Crossley | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1030 | Website https://www.indivior.com |
Full time employees 1030 | Website https://www.indivior.com | ||
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.